BRAF p. V600E Mutation as Acquired Resistance Mechanism of Lorlatinib in a ROS1 Rearrangement Lung Adenocarcinoma Patient with Liver Metastasis with Primary Ceritinib Resistance

Abstract

ALK-Anaplastic Lymphoma kinase; BM-Brain metastasis; BSC-Best supportive care; EGFR-Epidermal growth factor receptor; NGS-Next-generation sequencing; LM-Liver metastasis; NCCN-National comprehensive cancer network guidelines; NSCLC-Non-small cell lung cancer; ORR-Objective response rate; PD-Progressive disease; PFS-Progression-free survival; PR-Partial response; ROS1-C-ros oncogene 1 receptor kinase; SD-Stable disease; TKI-Tyrosine kinase inhibitor, CT-Computed tomography” “MRI-Magnetic resonance imaging” &Author Contributions: